Related references
Note: Only part of the references are listed.Synthesis and Pharmacology of Proteasome Inhibitors
Andreas Rentsch et al.
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION (2013)
Inhibitors for the Immuno- and Constitutive Proteasome: Current and Future Trends in Drug Development
Eva Maria Huber et al.
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION (2012)
Covalent and non-covalent reversible proteasome inhibition
Philipp Beck et al.
BIOLOGICAL CHEMISTRY (2012)
Immuno- and Constitutive Proteasome Crystal Structures Reveal Differences in Substrate and Inhibitor Specificity
Eva M. Huber et al.
CELL (2012)
Oxidative Homologation of Aldehydes to a-Ketoaldehydes by using Iodoform, o-Iodoxybenzoic Acid, and Dimethyl Sulf-oxide
Andrea Zall et al.
EUROPEAN JOURNAL OF ORGANIC CHEMISTRY (2012)
New Proteasome Inhibitors in Myeloma
Panisinee Lawasut et al.
CURRENT HEMATOLOGIC MALIGNANCY REPORTS (2012)
Elucidation of the alpha-Keto-Aldehyde Binding Mechanism: A Lead Structure Motif for Proteasome Inhibition
Melissa Ann Graewert et al.
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION (2011)
Nonproteasomal Targets of the Proteasome Inhibitors Bortezomib and Carfilzomib: a Link to Clinical Adverse Events
Shirin Arastu-Kapur et al.
CLINICAL CANCER RESEARCH (2011)
Pharmacokinetics, Pharmacodynamics, Metabolism, Distribution, and Excretion of Carfilzomib in Rats
Jinfu Yang et al.
DRUG METABOLISM AND DISPOSITION (2011)
Studies of the Synthesis of All Stereoisomers of MG-132 Proteasome Inhibitors in the Tumor Targeting Approach
Michal Mroczkiewicz et al.
JOURNAL OF MEDICINAL CHEMISTRY (2010)
A Phase 1 Dose Escalation Study of the Safety and Pharmacokinetics of the Novel Proteasome Inhibitor Carfilzomib (PR-171) in Patients with Hematologic Malignancies
Owen A. O'Connor et al.
CLINICAL CANCER RESEARCH (2009)
The relationship among tumor architecture, pharmacokinetics, pharmacodynamics, and efficacy of bortezomib in mouse xenograft models
Mark J. Williamson et al.
MOLECULAR CANCER THERAPEUTICS (2009)
A selective inhibitor of the immunoproteasome subunit LMP7 blocks cytokine production and attenuates progression of experimental arthritis
Tony Muchamuel et al.
NATURE MEDICINE (2009)
Resazurin assay of radiation response in cultured cells
S Anoopkumar-Dukie et al.
BRITISH JOURNAL OF RADIOLOGY (2005)
Tripeptide mimetics inhibit the 20 S proteasome by covalent bonding to the active threonines
HA Braun et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2005)
A phase 2 study of bortezomib in relapsed, refractory myeloma
PG Richardson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Crystal structure of epoxomicin:20S proteasome reveals a molecular basis for selectivity of α′,β′-epoxyketone proteasome inhibitors
M Groll et al.
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY (2000)
Share Paper
